Loading clinical trials...
Loading clinical trials...
Assessment of Efficacy and Safety of SPN-810 for the Treatment of Impulsive Aggression (IA) in Adolescent Subjects With Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction With Standard ADHD Treatment
Conditions
Interventions
SPN-810
Placebo
Locations
38
United States
ProScience
Culver City, California, United States
Neuropsychiatric Research Center of Orange County
Orange, California, United States
MCB Clinical Research Centers, LLC
Colorado Springs, Colorado, United States
Children's National Medical Center/Children's Research Institute
Washington D.C., District of Columbia, United States
Clinical Neuroscience Solutions, Inc
Jacksonville, Florida, United States
Meridien Research aka Florida Clinical Research Center, LLC
Lakeland, Florida, United States
Start Date
July 31, 2018
Primary Completion Date
January 22, 2020
Completion Date
January 22, 2020
Last Updated
April 24, 2024
NCT07439276
NCT04631042
NCT07189442
NCT06325813
NCT05683756
NCT07180758
Lead Sponsor
Supernus Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions